Validation: Membrane-Nucleation in iPSC Neurons

V2, Crosslink

🧫

Validation: Membrane-Nucleation in iPSC Neurons

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-membrane

🧫 Experiment Protocol Validationproposed

SUMMARY

# Validation: Membrane-Nucleation in iPSC Neurons ## Background and Rationale The validation study of membrane-nucleation mechanisms in iPSC-derived neurons represents a crucial translational bridge between fundamental biochemical discoveries and clinically relevant cellular models in Parkinson's disease research. This investigation builds upon compelling evidence that membrane lipid composition, particularly the presence of anionic phospholipids such as phosphatidylserine and phosphatidylinosit

METHODOLOGY NOTES

**Phase 1: iPSC-Derived Neuron Preparation (Weeks 1-6)** • Differentiate human iPSCs (n=6 cell lines, 3 healthy controls + 3 PD patients with SNCA mutations) into dopaminergic neurons using dual SMAD inhibition protocol • Validate neuronal identity at day 35-42 using immunofluorescence (TH+, MAP2+, β-tubulin III+) • Confirm dopaminergic phenotype with HPLC analysis of dopamine production • Seed neurons at 50,000 cells/well in 96-well imaging plates for membrane composition analysis **Phase 2: Membrane Lipid Composition Manipulation (Week 7)** • Treat neurons with lipid supplementation medium containing: PS (25-100 μM), PIP2 (10-50 μM), or vehicle control • Include positive control with rotenone (100 nM) and negative control with cholesterol supplementation • Incubate for 48-72 hours with daily medium changes • Validate membrane incorporation using mass spectrometry lipidomics (LC-MS/MS) **Phase 3: Alpha-Synuclein Analysis (Week 8)** • Fix cells at 24h, 48h, and 72h timepoints for imm

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.906317Z'}
summary	# Validation: Membrane-Nucleation in iPSC Neurons ## Background and Rationale The validation study of membrane-nucleation mechanisms in iPSC-derived neurons represents a crucial translational bridge b
entities	{'genes': ['CERS2/CLDN1/DNMT1'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	validation
primary_outcome	Validate Validation: Membrane-Nucleation in iPSC Neurons
methodology_notes	Phase 1: iPSC-Derived Neuron Preparation (Weeks 1-6) • Differentiate human iPSCs (n=6 cell lines, 3 healthy controls + 3 PD patients with SNCA mutations) into dopaminergic neurons using dual SMAD
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.906323', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

655

Outgoing

635

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Validation: Membrane-Nucleation in iPSC Neurons

derives from (16)

supports (5)

💬 Discussion